A college student from Anthony is speaking out after Blue Cross and Blue Shield of Kansas denied a medicine she has been ...

The federal government under the Trump administration has turned its focus to cutting costs, and a new report from the Blue Cross Blue ... to delay the entry of biosimilar drugs to the market ...

Cost Plus Drugs inked deals with MultiCare Health System, Network Health, Blue Cross and Blue Shield insurers and others ...

Nifty March Futures up by 0.08% at a premium of 97.45 points. Nifty Options March 13 Expiry: Maximum call open interest at 20 ...

Operating performance for the U.S. health insurance industry remained favorable through third-quarter 2024 with net income of $31 billion, although underwriting results have been pressured by Medicare ...

At the same time, 90% of U.S. prescriptions are either generics or biosimilars saving the U.S. healthcare system $445 billion in 2023 alone. Despite these achievements, there are important reforms ...

Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong first financial year as an independent company. After completing its spin-off from ...

Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's blockbuster drug Stelara, also known as ustekinumab. The drug is used to ...